Terms: = Colorectal cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Treatment
419 results:
1. Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic colorectal cancer.
Zhang XH; Zhou JQ; Wei Q; Li J; Xu T; Bai CM; Zhou JF; Wang XC
Discov Med; 2024 Jul; 36(186):1477-1485. PubMed ID: 39054718
[TBL] [Abstract] [Full Text] [Related]
2. Epidermal Growth Factor Receptor Targeting in colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.
Tardito S; Matis S; Zocchi MR; Benelli R; Poggi A
Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000238
[TBL] [Abstract] [Full Text] [Related]
3. Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer.
Wang W; Huang Y; Kong J; Lu L; Liao Q; Zhu J; Wang T; Yan L; Dai M; Chen Z; You J
Clin Transl Oncol; 2024 Aug; 26(8):1976-1987. PubMed ID: 38777950
[TBL] [Abstract] [Full Text] [Related]
4. Deep neural network for the prediction of KRAS, nras, and BRAF genotypes in left-sided colorectal cancer based on histopathologic images.
Li X; Chi X; Huang P; Liang Q; Liu J
Comput Med Imaging Graph; 2024 Jul; 115():102384. PubMed ID: 38759471
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Deciphering of colorectal cancer: Exploring Molecular Classifications and Analyzing the Interplay among Molecular Biomarkers MMR/MSI, KRAS, nras, BRAF and CDX2 - A Comprehensive Literature Review.
Ilie-Petrov AC; Cristian DA; Diaconescu AS; Chitul A; Blajin A; Popa A; Mandi DM; Negreanu R; Vieru C; Vrîncianu R; Ardeleanu CM
Chirurgia (Bucur); 2024 Apr; 119(2):136-155. PubMed ID: 38743828
[No Abstract] [Full Text] [Related]
6. Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic colorectal cancer Patients: A Multicenter Retrospective Analysis.
Basso M; Signorelli C; Calegari MA; Lucchetti J; Zurlo IV; Dell'Aquila E; Arrivi G; Zoratto F; Santamaria F; Saltarelli R; Trovato G; Caira G; Angotti L; Schirripa M; Anghelone A; Schietroma F; Chilelli MG; Salvatore L; Pozzo C; Tortora G
Target Oncol; 2024 May; 19(3):371-382. PubMed ID: 38613732
[TBL] [Abstract] [Full Text] [Related]
7. Epidemiological and clinicopathological features of KRAS, nras, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer.
Wang W; Wang R; Han X; Zhang W; Zhu L; Gu Y
Medicine (Baltimore); 2024 Apr; 103(14):e37693. PubMed ID: 38579072
[TBL] [Abstract] [Full Text] [Related]
8. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or nras Mutant Advanced Solid Tumors.
Corcoran RB; Do KT; Kim JE; Cleary JM; Parikh AR; Yeku OO; Xiong N; Weekes CD; Veneris J; Ahronian LG; Mauri G; Tian J; Norden BL; Michel AG; Van Seventer EE; Siravegna G; Camphausen K; Chi G; Fetter IJ; Brugge JS; Chen H; Takebe N; Penson RT; Juric D; Flaherty KT; Sullivan RJ; Clark JW; Heist RS; Matulonis UA; Liu JF; Shapiro GI
Clin Cancer Res; 2024 May; 30(9):1739-1749. PubMed ID: 38456660
[TBL] [Abstract] [Full Text] [Related]
9. Concurrent nras-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
[TBL] [Abstract] [Full Text] [Related]
10. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.
Ciepiela I; Szczepaniak M; Ciepiela P; Hińcza-Nowak K; Kopczyński J; Macek P; Kubicka K; Chrapek M; Tyka M; Góźdź S; Kowalik A
Sci Rep; 2024 Feb; 14(1):4619. PubMed ID: 38409377
[TBL] [Abstract] [Full Text] [Related]
11. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.
Karapetis CS; Liu H; Sorich MJ; Pederson LD; Van Cutsem E; Maughan T; Douillard JY; O'Callaghan CJ; Jonker D; Bokemeyer C; Sobrero A; Cremolini C; Chibaudel B; Zalcberg J; Adams R; Buyse M; Peeters M; Yoshino T; de Gramont A; Shi Q
Br J Cancer; 2024 May; 130(8):1269-1278. PubMed ID: 38402342
[TBL] [Abstract] [Full Text] [Related]
12. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
[TBL] [Abstract] [Full Text] [Related]
13. Using tumor habitat-derived radiomic analysis during pretreatment
Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
[TBL] [Abstract] [Full Text] [Related]
14. Sotorasib Is a Pan-rasG12C Inhibitor Capable of Driving Clinical Response in nrasG12C cancers.
Rubinson DA; Tanaka N; Fece de la Cruz F; Kapner KS; Rosenthal MH; Norden BL; Barnes H; Ehnstrom S; Morales-Giron AA; Brais LK; Lemke CT; Aguirre AJ; Corcoran RB
Cancer Discov; 2024 May; 14(5):727-736. PubMed ID: 38236605
[TBL] [Abstract] [Full Text] [Related]
15. Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel.
Rencuzogullari A; Bisgin A; Erdogan KE; Gumus S; Yalav O; Boga I; Sonmezler O; Eray IC
Ann Ital Chir; 2023; 94():605-611. PubMed ID: 38131395
[TBL] [Abstract] [Full Text] [Related]
16. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high colorectal cancer after treatment Termination.
Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
[TBL] [Abstract] [Full Text] [Related]
17. A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic colorectal cancer.
Lee KW; Han SW; Kim TW; Ahn JB; Baek JY; Cho SH; Lee H; Kim JW; Kim JW; Kim TY; Hong YS; Beom SH; Cha Y; Choi Y; Kim S; Bang YJ
Cancer Res Treat; 2024 Apr; 56(2):590-601. PubMed ID: 38062706
[TBL] [Abstract] [Full Text] [Related]
18. Characteristic Mutational Damages in Gastric and colorectal Adenocarcinomas.
Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Kaidarova D; Shatkovskaya O
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3939-3947. PubMed ID: 38019254
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract] [Full Text] [Related]
20. Overcoming the hurdles: surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer.
Sackstein PE; Chintapally N; Wilgucki M; Hartley ML; Alqahtani A; Weinberg BA
Clin Adv Hematol Oncol; 2023 Nov; 21(11):572-583. PubMed ID: 37948593
[TBL] [Abstract] [Full Text] [Related]
[Next]
